Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Start-up Entasis has hefty funding round
by Lisa M. Jarvis
April 11, 2016
| A version of this story appeared in
Volume 94, Issue 15
The antibiotics start-up Entasis Therapeutics has raised $50 million in its second round of financing. Entasis was spun off from AstraZeneca in early 2015 after the big pharma firm failed to find a buyer for the unit. AstraZeneca initially committed up to $40 million to the new company; this next funding round, from outside firms, will help support Entasis’s most advanced drug candidate, ETX0914, a gyrase inhibitor in Phase II studies to treat gonorrhea.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter